abbvie glp-1 receptor agonist medications How Agonists Evolved from Diabetes to Weight Loss Treatments abbvie glp-1 receptor agonists weight

A 2025 systematic review and meta-analysis of 23 randomized controlled trials found that berberine reduced body weight by an average of about 0.88 kg, or roughly 2 pounds

It effectively controls blood sugar levels and helps people lose weight, but it doesn't change the glucagon system directly

K., Hocquard, A., Avila, G., Pagana, A., Chen, A., & John, T

Treatment satisfaction significantly improved among GLP-1 users in six studies

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data